The prevalence of “pure” autosomal dominant hereditary spastic paraparesis in the island of Ireland

P Mc Monagle, S Webb, M Hutchinson

Methods

Hereditary spastic paraparesis (HSP) comprises a group of inherited neurodegenerative disorders with the shared characteristic of slowly progressive spasticity and weakness of the legs. It is subdivided into “pure” or “complicated” forms depending on whether the paraparesis exists in isolation or with other major clinical features. Genetic heterogeneity is marked and autosomal dominant (AD), autosomal recessive (AR), and X linked inheritance is described for both pure and complicated forms. Genetic loci have been identified for all types of HSP.

The prevalence of ADHSP in Ireland was estimated to be 1.27/100 000 population. The high proportion of asymptomatic cases and obligate carriers means that this condition is likely to be underdiagnosed.

HSP is clinically and genetically heterogeneous. “Pure” autosomal dominant (AD) HSP is most common and eight genetic loci are identified to date. Previous studies have included autosomal recessive and sporadic cases in prevalence calculations. This study aimed to determine the prevalence and features of pure ADHSP in the island of Ireland.

Objective: Hereditary spastic paraparesis (HSP) is clinically and genetically heterogeneous. “Pure” autosomal dominant (AD) HSP is most common and eight genetic loci are identified to date. Previous studies have included autosomal recessive and sporadic cases in prevalence calculations. This study aimed to determine the prevalence and features of pure ADHSP in the island of Ireland.

Methods: Index cases were identified from a 5 year survey of all adult and paediatric neurologists, clinical geneticists, hospital records, and hospital inpatient enquiry system data in Ireland, north and south. Families were examined by two neurologists and classified as affected or unaffected according to specific criteria. The prevalence date was set at 1 June 2000 and the midyear population estimate for the previous year was 5.436 million.

Results: Eighty two patients with pure ADHSP and a further 12 obligate carriers from 19 families were identified. In total 69 patients with pure ADHSP were alive and resident in Ireland at the prevalence date. Twenty nine per cent of these were asymptomatic but with signs of paraparesis.

Conclusions: The prevalence of ADHSP in Ireland estimated to be 1.27/100 000 population. The high proportion of asymptomatic cases and obligate carriers means that this condition is likely to be underdiagnosed.

Received 23 April 2001
In revised form 29 August 2001
Accepted 3 September 2001

Abbreviations: HSP, hereditary spastic paraparesis; AD, autosomal dominant; AR, autosomal recessive; HIPE, hospital in patient enquiry system; PR, prevalence rate
using the criteria of Harding.\textsuperscript{1,2} Cases with mild ataxia and mild distal amyotrophy as well as late onset dementia were considered to have pure HSP as these are uncommon but recognised findings in patients with SPAST mutations, the major disease gene for pure ADHSP.

### Statistical methods

A point prevalence was calculated using the 1999 midyear estimate of the population of the Republic of Ireland and Northern Ireland as the denominator. Age, sex, and region specific rates were calculated with 95% confidence intervals (95% CIs) derived from the Poisson distribution to allow for sampling errors. Regional variation was analysed with a one sample z test and rates were age adjusted to the overall population using the direct method.

### RESULTS

In total, we identified 82 people with signs of paraparesis from 19 Irish families with pure ADHSP. The major source of index cases was from neurologists (n=15), followed by clinical geneticists (n=3), and search of hospital records (n=1), and the HIPPE reporting system disclosed no additional cases. Four families demonstrated mutations in the SPATA gene on chromosome 2p (n=16), a further family (n=10) did not have an identifiable mutation in this gene despite evidence of strong linkage to SPG4 (maximum lod score=3.86 at zero recombination). In three families involvement of SPATA was excluded (n=22) whereas the genetic status of the remaining 11 families (n=22) could not be determined. Clinical and genetic details of these families are described elsewhere.\textsuperscript{11,14}

At prevalence day, eight affected people were living abroad though they had all emigrated before the study began. Another five had died towards the middle of the study period, leaving 69 alive and resident in Ireland, which gives a crude prevalence of 1.2/100 000 population (95% CI 0.99 to 1.61). Thirty three females were affected (age adjusted prevalence=1.19/100 000, 95% CI 0.83 to 1.69) and 36 males (age adjusted prevalence=1.33/100 000, 95% CI 0.94 to 1.85) with no significant difference between the rate for either group (z=0.3). The age and sex prevalence of ADHSP is illustrated in table 1. A higher prevalence is seen for men aged 40 to 49 (z=0.14, p=0.8) and for women aged 60 to 69 (z=−0.105, p=0.92) but this was not statistically significant for either. Twenty of the 69 with signs of HSP were asymptomatic (29%) and therefore unaware of any abnormality. These cases were only detected through examination of the extended family in each case. A further 12 people were thought to be obligate gene carriers based on haplotype, mutation, and family tree analysis but were not included in data calculations.

Relative prevalence rates for each regional authority are outlined in figure 1. The Dublin area had the highest rate of pure ADHSP at 2.46/100 000 population (95% CI 1.48 to 3.37). This was significantly higher than the overall population rate (z=3.51, p<0.01) and persisted after adjustment for age. This is the capital of the Republic of Ireland and the main population centre for the entire island. The lowest rate was found in the border region between Northern Ireland and Republic of Ireland (0.24/100 000; 95% CI 0.06 to 1.36).

### Table 1 Age specific prevalence of “pure” ADHSP in Ireland

<table>
<thead>
<tr>
<th>Age</th>
<th>Female</th>
<th>Rate/100000</th>
<th>95% CI</th>
<th>Male</th>
<th>Rate/100000</th>
<th>95% CI</th>
<th>Total</th>
<th>Rate/100000</th>
<th>95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>0–9</td>
<td>0.3794</td>
<td>0.53</td>
<td>0.06 to 1.9</td>
<td>0.4002</td>
<td>0.75</td>
<td>0.15 to 2.19</td>
<td>0.7796</td>
<td>0.64</td>
<td>0.21 to 1.5</td>
</tr>
<tr>
<td>10–19</td>
<td>0.4408</td>
<td>0.68</td>
<td>0.14 to 1.99</td>
<td>0.4638</td>
<td>1.29</td>
<td>0.47 to 2.82</td>
<td>0.9046</td>
<td>0.99</td>
<td>0.45 to 1.89</td>
</tr>
<tr>
<td>20–29</td>
<td>0.417</td>
<td>0.96</td>
<td>0.26 to 2.46</td>
<td>0.4592</td>
<td>0.93</td>
<td>0.25 to 2.39</td>
<td>0.8462</td>
<td>0.95</td>
<td>0.41 to 1.86</td>
</tr>
<tr>
<td>30–39</td>
<td>0.3995</td>
<td>1.5</td>
<td>0.55 to 3.27</td>
<td>0.3887</td>
<td>1.29</td>
<td>0.42 to 3.0</td>
<td>0.7882</td>
<td>1.1</td>
<td>0.7 to 2.5</td>
</tr>
<tr>
<td>40–49</td>
<td>0.3492</td>
<td>1.15</td>
<td>0.31 to 2.93</td>
<td>0.3459</td>
<td>2.6</td>
<td>1.19 to 4.94</td>
<td>0.6951</td>
<td>1.87</td>
<td>1.0 to 3.2</td>
</tr>
<tr>
<td>50–59</td>
<td>0.2813</td>
<td>1.07</td>
<td>0.22 to 3.12</td>
<td>0.2828</td>
<td>1.06</td>
<td>0.22 to 3.1</td>
<td>0.5641</td>
<td>1.06</td>
<td>0.39 to 2.32</td>
</tr>
<tr>
<td>60–69</td>
<td>0.211</td>
<td>3.79</td>
<td>1.64 to 7.47</td>
<td>0.1982</td>
<td>2.02</td>
<td>0.55 to 5.17</td>
<td>0.4092</td>
<td>1.29</td>
<td>0.53 to 3.85</td>
</tr>
<tr>
<td>70–79</td>
<td>0.1735</td>
<td>3.73</td>
<td>0.36 to 5.05</td>
<td>0.1299</td>
<td>1.54</td>
<td>0.19 to 5.56</td>
<td>0.3034</td>
<td>1.65</td>
<td>0.53 to 3.85</td>
</tr>
<tr>
<td>80+</td>
<td>0.097</td>
<td>0.0</td>
<td>0.0 to 3.8</td>
<td>0.049</td>
<td>0.0</td>
<td>0.0 to 7.53</td>
<td>0.1459</td>
<td>0.0</td>
<td>0.0 to 2.53</td>
</tr>
<tr>
<td>Age adjusted total</td>
<td>2.7487</td>
<td>1.19</td>
<td>0.83 to 1.69</td>
<td>2.6877</td>
<td>1.33</td>
<td>0.94 to 1.85</td>
<td>5.4363</td>
<td>1.27</td>
<td>0.99 to 1.61</td>
</tr>
</tbody>
</table>

### Table 2 Prevalences in previous studies of hereditary spastic paraparesis

<table>
<thead>
<tr>
<th>Author</th>
<th>Period of study</th>
<th>Area of study</th>
<th>Population</th>
<th>Patient sources</th>
<th>Clinical features</th>
<th>Inheritance</th>
<th>Cases</th>
<th>Prevalence/100000</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chen et al\textsuperscript{25}</td>
<td>1960–1966</td>
<td>Guam</td>
<td>37975</td>
<td>National Institute of Neurological Diseases and Blindness</td>
<td>Pure</td>
<td>AD/AR-HSP and sporadic AD-HSP</td>
<td>7</td>
<td>18.4</td>
</tr>
<tr>
<td>Skre\textsuperscript{16}</td>
<td>1960–1968</td>
<td>Western Norway</td>
<td>725000</td>
<td>University hospital in Bergen</td>
<td>Pure and complicated AD-HSP</td>
<td>31</td>
<td>12.1</td>
<td></td>
</tr>
<tr>
<td>Werderlin\textsuperscript{17} and Werderlin\textsuperscript{17}</td>
<td>1961–1975</td>
<td>Zealand (Denmark)</td>
<td>1179000</td>
<td>All hospitals in Zealand</td>
<td>Pure and complicated AD-HSP</td>
<td>23</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td>Brignoli et al\textsuperscript{19}</td>
<td>1945–1982</td>
<td>Turin (Italy)</td>
<td>2327996</td>
<td>Age 10 to 50</td>
<td>Not stated</td>
<td>AD-HSP</td>
<td>31</td>
<td>0.7</td>
</tr>
<tr>
<td>Sridharan et al\textsuperscript{20}</td>
<td>1984</td>
<td>Bengaluru (India)</td>
<td>519000</td>
<td>District and regional hospitals, nursing homes and disability centres</td>
<td>Not stated</td>
<td>AD-HSP</td>
<td>11</td>
<td>2.1</td>
</tr>
<tr>
<td>Polo et al\textsuperscript{21}</td>
<td>1974–1986</td>
<td>Cantabria (Spain)</td>
<td>510000</td>
<td>Neurology department of the regional hospital</td>
<td>Pure and complicated</td>
<td>AD-HSP</td>
<td>49</td>
<td>9.6</td>
</tr>
<tr>
<td>Filla et al\textsuperscript{22}</td>
<td>1989</td>
<td>Malaga (Spain)</td>
<td>33021</td>
<td>Mail survey of 847 hospital physicians and GPs</td>
<td>Pure and complicated</td>
<td>AD-HSP</td>
<td>9</td>
<td>2.1</td>
</tr>
<tr>
<td>Hiyama et al\textsuperscript{23}</td>
<td>1988–1989</td>
<td>Japan</td>
<td>123000000</td>
<td>Mail survey of hospitals with 200 plus beds</td>
<td>Pure and complicated</td>
<td>AD-HSP</td>
<td>109</td>
<td>0.17</td>
</tr>
<tr>
<td>Leone et al\textsuperscript{24}</td>
<td>1981–1991</td>
<td>Valle d’Aosta (Italy)</td>
<td>115270</td>
<td>Departments in the regional hospital and local disability centres</td>
<td>Pure and complicated</td>
<td>AD-HSP</td>
<td>5</td>
<td>4.3</td>
</tr>
<tr>
<td>Silva et al\textsuperscript{25}</td>
<td>1994</td>
<td>Viana do Castelo (Portugal)</td>
<td>250061</td>
<td>District &amp; regional hospitals, disability centres and GPs</td>
<td>Pure and complicated</td>
<td>AD-HSP</td>
<td>5</td>
<td>2</td>
</tr>
<tr>
<td>Current study</td>
<td>1995–2000</td>
<td>Ireland</td>
<td>5436000</td>
<td>Neurologists, geneticists, and hospital records.</td>
<td>Pure</td>
<td>AD-HSP</td>
<td>69</td>
<td>1.27</td>
</tr>
</tbody>
</table>

www.jnnp.com
CONCLUSIONS

In the course of a 5-year population-based survey of HSP in the north and south of Ireland, we identified 69 cases with pure ADHSP to give a crude point prevalence of 1.27/100,000. Equal prevalence was seen for both men and women in keeping with autosomal inheritance. Regional variation showed the greatest numbers in the Dublin area with 2.46/100,000 population. The accuracy of this estimate of pure ADHSP prevalence depends on the complete ascertainment of all cases in Ireland. Capture-recapture analysis based on multiple sources can be used to estimate this but was not suited to our study. Multiple sources identified each family rather than each case and the sources themselves were not truly independent. Active family tracing by the investigators gave the final count and acted effectively as a single source. In addition, the high proportion of asymptomatic cases (29%) means complete ascertainment will probably be an underestimate. Other difficulties arise because of the potential for misdiagnosis, not considering HSP as a possible diagnosis, and the failure to examine relatives of patients with apparently sporadic pure spastic paraparesis. Primary progressive multiple sclerosis, cerebral palsy and arthritis are common diagnostic errors that arise if patients are not seen by a neurologist. However, we think that we have ascertained all cases of pure ADHSP that came to neurological attention, certainly in the Dublin area, as well as a significant proportion of other cases from direct examination of at-risk family members. There are only a few neurologists in Ireland. All were written to annually during the study period and all replied either verbally or in writing to our requests for patients thus providing the major source for our families. Only one additional case was disclosed from review of the medical records in four neurological centres in Ireland whereas the HIPE reporting system disclosed none.

The highest rates of pure ADHSP are found in the Dublin area which is not surprising because it is the main population centre (20% of the entire island) and has the highest number of neurologists (9) in the country. We found no evidence that patients with HSP migrated to population centres such as Dublin for treatment or for any other reasons beyond the usual socioeconomic forces. This was evident through direct questioning and review of records and was facilitated by knowing the whereabouts of other family members, parents, and the original family home. Many patients were unaware of any abnormality and therefore required no medical input. Those who did, contacted the health services primarily for diagnosis and most were not routinely followed up in neurology clinics. In all cases, those who did attend for physiotherapy or adjustment of medications lived within easy driving distance (3 hours maximum) so migration for treatment or assessment was not necessary. Another factor militating against migration is the relatively late onset of symptoms. In SPAST pedigrees, this is usually between the ages of 28 and 30 when many have married and started families making movement difficult. Other potential reasons for geographic variation, beyond chance, would include racial differences in the population distribution between regions. This did not apply in our study as all cases and families were the same race. Environmental exposure to toxins or infections in urban areas, causing spontaneous mutations in HSP genes, is another possible cause. However, the frequent finding of gait disturbance in family members, living in rural areas, dating back generations argues against this. Another factor is difference in diagnostic and referral practice between regions and physicians and this we think is more likely to be significant. Patients were frequently misdiagnosed as having multiple sclerosis or arthritis before being seen by a neurologist. The concentration of neurologists in the Dublin area all meet on a weekly basis which means that they were more likely to refer patients to the study, which was based in a Dublin teaching hospital. We think, therefore, that the higher rates of HSP in the Dublin area probably reflect a greater likelihood of being diagnosed with HSP and referred to the study; Consequently, while still probably an underestimate, we think that the prevalence rate here gives the best estimate of the “true” rate of pure ADHSP in Ireland as a whole.

Comparison with other prevalence studies in HSP is fraught with difficulty because they are not often performed and lack uniformity of diagnostic criteria. Some authors include apparently sporadic cases in their calculations of HSP prevalence and others include complicated with pure cases and autosomal recessive with dominant families. It is not surprising, therefore, that our rate falls in the lower end of the reported range of HSP prevalence (table 2). However, the prevalence rate for the Dublin area (2.46/100,000; 95% CI 1.48 to 3.37) is consistent with the reports of others. Ours is the first prospective study to examine the prevalence of pure ADHSP in an entire country using specific classification and diagnostic criteria and excluding those with recessive inheritance or complicated phenotypes. It is clear that even pure ADHSP represents more than one disease and our study therefore reflects the frequency of a particular phenotype rather than a specific disease. In the future prevalence studies will be based on the presence of specific gene mutations, but for uncommon, genetically heterogeneous disorders such as HSP this is not yet possible.

ACKNOWLEDGEMENTS

We are grateful to patients and their families for their participation and to all adult and paediatric neurologists in Ireland, north and south, who have referred patients for the study.

Authors’ affiliations
P Mc Monagle, S Webb, M Hutchinson, Department of Neurology, St Vincent’s University Hospital, Elm Park, Dublin 4, Ireland

REFERENCES
The prevalence of "pure" autosomal dominant hereditary spastic paraparesis in the island of Ireland

P McMonagle, S Webb and M Hutchinson

*J Neurol Neurosurg Psychiatry* 2002 72: 43-46
doi: 10.1136/jnnp.72.1.43

Updated information and services can be found at:
http://jnnp.bmj.com/content/72/1/43

These include:

**References**
This article cites 22 articles, 8 of which you can access for free at:
http://jnnp.bmj.com/content/72/1/43#BIBL

**Email alerting service**
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Notes**